• Explore /
  • Poster
  • / Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.

Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.

Abstract Poster

Authors

null

Sundar Jagannath

Mount Sinai Medical Center, New York, NY

Sundar Jagannath , Craig C. Hofmeister , Rachid C. Baz , David Samuel DiCapua Siegel , Ravi Vij , Christine Chen , Sagar Lonial , Kenneth Carl Anderson , Min Chen , Mohamed H. Zaki , Paul Gerard Guy Richardson

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Lymphoma and Plasma Cell Disorders

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT00833833

Citation

J Clin Oncol 31, 2013 (suppl; abstr 8532)

DOI

10.1200/jco.2013.31.15_suppl.8532

Abstract #

8532

Poster Bd #

12

Abstract Disclosures

Similar Posters

First Author: David Samuel DiCapua Siegel

First Author: Philippe Moreau

First Author: Cyrille Touzeau

First Author: Andrew Jenho Yee